See more : Metalore Resources Limited (MET.V) Income Statement Analysis – Financial Results
Complete financial analysis of Selecta Biosciences, Inc. (SELB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Selecta Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Federal National Mortgage Association (FNMAL) Income Statement Analysis – Financial Results
- BankInvest Optima 55 Akk. KL (BIV55A.CO) Income Statement Analysis – Financial Results
- Advanced Fiber Resources (Zhuhai), Ltd. (300620.SZ) Income Statement Analysis – Financial Results
- Equitas Holdings Limited (EQUITAS.NS) Income Statement Analysis – Financial Results
- E for L Aim Public Company Limited (EFORL.BK) Income Statement Analysis – Financial Results
Selecta Biosciences, Inc. (SELB)
About Selecta Biosciences, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 110.78M | 85.08M | 16.60M | 6.68M | 903.00K | 207.00K | 8.08M | 6.01M | 3.04M |
| Cost of Revenue | 0.00 | 72.38M | 68.74M | 54.51M | 42.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 38.40M | 16.34M | -37.91M | -36.07M | 903.00K | 207.00K | 8.08M | 6.01M | 3.04M |
| Gross Profit Ratio | 0.00% | 34.66% | 19.21% | -228.40% | -540.15% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 71.84M | 72.38M | 68.74M | 54.51M | 42.74M | 47.69M | 45.17M | 29.70M | 22.98M | 10.49M |
| General & Administrative | 40.58M | 23.86M | 20.94M | 18.91M | 16.39M | 18.24M | 18.83M | 13.05M | 8.34M | 7.95M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 40.58M | 23.86M | 20.94M | 18.91M | 16.39M | 18.24M | 18.83M | 13.05M | 8.34M | 7.95M |
| Other Expenses | 0.00 | 330.00K | 15.00K | 89.00K | -1.31M | 10.00K | -152.00K | 4.00K | -26.00K | -44.00K |
| Operating Expenses | 112.42M | 96.24M | 89.67M | 73.42M | 59.13M | 65.93M | 63.99M | 42.75M | 31.32M | 18.44M |
| Cost & Expenses | 112.42M | 96.24M | 89.67M | 73.42M | 59.13M | 65.93M | 63.99M | 42.75M | 31.32M | 18.44M |
| Interest Income | 0.00 | 958.00K | 2.80M | 1.30M | 834.00K | 1.05M | 617.00K | 234.00K | 171.00K | 111.00K |
| Interest Expense | -2.83M | 3.03M | 2.84M | 1.56M | 1.52M | 1.49M | 1.21M | 1.25M | 948.00K | 552.00K |
| Depreciation & Amortization | 764.00K | 1.62M | 15.00K | 89.00K | -1.31M | 975.00K | 750.00K | 802.00K | 1.04M | 864.00K |
| EBITDA | -86.42M | 16.16M | -4.58M | -56.73M | -53.76M | -65.01M | -63.94M | -34.67M | -24.29M | -14.58M |
| EBITDA Ratio | 0.00% | 14.58% | -5.39% | -341.82% | -805.17% | -7,199.56% | -30,886.96% | -428.88% | -404.03% | -479.57% |
| Operating Income | -86.42M | 14.54M | -4.60M | -56.82M | -52.46M | -65.02M | -63.78M | -34.67M | -25.30M | -15.40M |
| Operating Income Ratio | 0.00% | 13.12% | -5.40% | -342.36% | -785.61% | -7,200.66% | -30,813.53% | -428.92% | -420.96% | -506.55% |
| Total Other Income/Expenses | -152.29M | 20.23M | -5.12M | -12.06M | -2.90M | -314.00K | -1.54M | -1.54M | 130.00K | 2.52M |
| Income Before Tax | -238.71M | 34.77M | -9.72M | -68.88M | -55.35M | -65.34M | -65.32M | -36.21M | -25.17M | -12.88M |
| Income Before Tax Ratio | 0.00% | 31.39% | -11.43% | -414.99% | -828.97% | -7,235.44% | -31,556.04% | -447.98% | -418.80% | -423.68% |
| Income Tax Expense | 19.00M | -609.00K | 15.97M | 911.00K | -1.81M | 1.18M | 304.00K | 455.00K | 922.00K | 508.00K |
| Net Income | -219.71M | 35.38M | -25.69M | -69.79M | -53.54M | -65.34M | -65.32M | -36.21M | -25.17M | -12.88M |
| Net Income Ratio | 0.00% | 31.94% | -30.19% | -420.48% | -801.80% | -7,235.44% | -31,556.04% | -447.98% | -418.80% | -423.68% |
| EPS | 0.00 | 0.24 | -0.22 | -0.69 | -1.18 | -2.92 | -3.20 | -3.45 | -1.96 | -1.00 |
| EPS Diluted | 0.00 | 0.10 | -0.22 | -0.69 | -1.18 | -2.92 | -3.20 | -3.45 | -1.96 | -1.00 |
| Weighted Avg Shares Out | 155.11B | 144.76M | 114.33M | 101.20M | 45.55M | 22.39M | 20.43M | 10.49M | 12.87M | 12.87M |
| Weighted Avg Shares Out (Dil) | 155.11B | 145.87M | 114.33M | 101.20M | 45.55M | 22.39M | 20.43M | 10.49M | 12.87M | 12.87M |
5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets
Selecta Biosciences Announces Strategic Licensing Agreement with Takeda to Develop Next-Generation Gene Therapies for Patients with Lysosomal Storage Disorders
Selecta Biosciences to Participate in Cantor Virtual Global Healthcare Conference
Selecta Biosciences Announces Appointment of Kevin Tan as Chief Financial Officer
Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q2 2021 Results - Earnings Call Transcript
Selecta Biosciences: Q2 Earnings Insights
New Strong Sell Stocks for July 14th
Selecta Biosciences to Participate at the William Blair Biotech Focus Conference 2021
Selecta Biosciences Has Multiple Shots On Goal
Source: https://incomestatements.info
Category: Stock Reports